Interestingly, FASN is a major regulator of neoplastic lipogenesis and is commonly found overexpressed in many cancers [65], is a metabolic oncogene that has been suggested as an attractive target for cancer therapy [76] and, given the ability of TRIB1 and -3 to mark proteins for proteasomal degradation, this interaction represents a promising therapeutic approach for breast cancer. This evidence concerns the gene FASN and breast cancer.